Chemical exchange saturation transfer (CEST) imaging of lactate (LATEST)
CEST imaging technique and MR scanning are used as an MRI method for detecting levels of lactate in vivo by exploiting the exchange of —OH protons on lactate with bulk water. In accordance with this method, one first obtains a lactate CEST MRI map of a slice of the body of a patient. A contrast agent such as pyruvate, glucose or glutamine is administered and a post-administration CEST MRI map is obtained. The difference in the spatial maps indicates the level of expression of lactate in the tissue of interest.
1. A magnetic resonance imaging (MM) method comprising:
(i) applying a lactate-mediated Chemical Exchange Saturation Transfer (CEST) saturation pulse protocol to a patient at a range of frequency offsets around a frequency of exchangeable protons of lactate as well as the same frequency offsets on the opposite side of a water resonance, the lactate-mediated Chemical Exchange Saturation Transfer (CEST) saturation pulse protocol comprising a saturation pulse at a frequency of 0.4 ppm offset from water and a saturation pulse duration and amplitude optimized for lactate-mediated CEST;
(ii) acquiring a magnetic resonance (MR) image of a slice of the body of said patient to which the lactate-mediated CEST saturation pulse protocol has been applied in order to obtain an initial lactate-mediated CEST MRI map;
(iii) administering an effective amount of a contrast agent to said patient, wherein the contrast agent is a metabolic precursor of lactate;
(iv) after administering the effective amount of the contrast agent to said patient, acquiring a second MR image of said slice of the body of said patient to which the lactate-mediated CEST saturation pulse protocol has been applied to obtain a second lactate-mediated CEST MRI map;
(v) determining a lactate-mediated CEST contrast image by taking a ratio of a difference image obtained by subtraction of saturation images obtained in steps (ii) and (iv) with saturation applied at both positive and negative frequencies with respect to water resonance and an image with no saturation; and
(vi) displaying the lactate-mediated CEST contrast image as an indication of the level of expression of lactate in said slice of the body of the patient.
2. The magnetic resonance imaging method of claim 1 , further comprising adjusting an amplitude and duration of the lactate-mediated CEST saturation pulse protocol based on the rate of exchange of lactate protons.
3. The magnetic resonance imaging method of claim 2 , wherein the lactate exchangeable protons are —OH.
4. The magnetic resonance imaging method of claim 1 , wherein the lactate-mediated CEST saturation pulse protocol comprises a variable number of pulses with variable shapes including rectangle and Hanning windowed rectangle, variable amplitudes, variable durations, and variable delays.
5. The magnetic resonance imaging method of claim 1 , wherein a plurality of lactate-mediated CEST contrast images are determined over a period of time.
6. The magnetic resonance imaging method of claim 5 , further comprising displaying the lactate-mediated CEST contrast image as an indication of the level of expression of lactate over time.
7. The magnetic resonance imaging method of claim 1 , wherein the contrast agent is administered orally, nasally, intravenously, by infusion, transdermally, or intraperitoneally to the patient.
8. The magnetic resonance imaging method of claim 7 , wherein the contrast agent is administered by infusion, and the infusion takes place over a period of time wherein multiple lactate-mediated CEST contrast images may be obtained.
9. The magnetic resonance imaging method of claim 1 , further comprising B 0 and B 1 correction of the saturation images before subtracting the saturation images.
10. The magnetic resonance imaging method of claim 1 , further comprising obtaining one or more conventional MM images of said patient.
11. The magnetic resonance imaging method of claim 1 , wherein lactate accumulates in abnormal tissue differently than in normal or healthy tissue.
12. The magnetic resonance imaging method of claim 11 , wherein the abnormal tissue is neoplastic tissue, inflamed tissue, ischemic tissue, degenerated tissue, or fibrotic tissue.
13. The magnetic resonance imaging method of claim 12 , wherein the neoplastic tissue comprises cancerous tissue.
14. The magnetic resonance imaging method of claim 11 , wherein the lactate accumulates in abnormal tissue at a different rate than in normal or healthy tissue.
15. The magnetic resonance imaging method of claim 14 , wherein the rate of accumulation of lactate in abnormal and normal or healthy tissue is calculated.
16. A method of monitoring the effectiveness of a pharmaceutical agent in treating a condition in a patient, said method comprising:
(i) applying a lactate-mediated Chemical Exchange Saturation Transfer (CEST) saturation pulse protocol to a patient at a range of frequency offsets around a frequency of exchangeable protons of lactate as well as the same frequency offsets on the opposite side of a water resonance, the lactate-mediated Chemical Exchange Saturation Transfer (CEST) saturation pulse protocol incorporating a saturation pulse frequency offset of 0.4 ppm from water;
(ii) acquiring a magnetic resonance (MR) image of a slice of the body of said patient to which the lactate-mediated CEST saturation pulse protocol has been applied in order to obtain an initial lactate-mediated CEST Mill map;
(iii) administering a pharmaceutical agent to said patient;
(iv) administering an effective amount of a contrast agent to said patient, wherein the contrast agent is a metabolic precursor of lactate;
(v) after administering the pharmaceutical agent and the effective amount of the contrast agent to said patient, acquiring a second MR image of said slice of the body of said patient to which the lactate-mediated CEST saturation pulse protocol has been applied to obtain a second lactate-mediated CEST MRI map;
(vi) determining a lactate-mediated CEST contrast image by taking a ratio of a difference image obtained by subtraction of saturation images obtained in steps (ii) and (v) with saturation applied at both positive and negative frequencies with respect to water resonance and an image with no saturation; and
(vii) displaying the lactate-mediated CEST contrast image as an indication of the level of expression of lactate.
17. A method of distinguishing abnormal tissue from normal tissue in a patient, said method comprising:
(i) applying to a suspected abnormal tissue a lactate-mediated Chemical Exchange Saturation Transfer (CEST) saturation pulse protocol at a range of frequency offsets around a frequency of exchangeable protons of lactate as well as the same frequency offsets on the opposite side of a water resonance, the lactate-mediated Chemical Exchange Saturation Transfer (CEST) saturation pulse protocol incorporating a saturation frequency offset of 0.4 ppm from water;
(ii) acquiring a magnetic resonance (MR) image of a said suspected abnormal tissue to which the lactate-mediated CEST saturation pulse protocol has been applied in order to obtain an initial lactate-mediated CEST MRI map;
(iii) administering an effective amount of a contrast agent to said patient, wherein the contrast agent is a metabolic precursor of lactate selected from pyruvate, glucose, glutamine, or a combination thereof;
(iv) after administering the effective amount of the contrast agent to said patient, acquiring a second MR image of said suspected abnormal tissue to which the lactate-mediated CEST saturation pulse protocol has been applied to obtain a second lactate-mediated CEST MRI map of the area of the suspected abnormal tissue;
(v) determining a lactate-mediated CEST contrast image by taking a ratio of a difference image obtained by subtraction of saturation images obtained in steps (ii) and (iv) with saturation applied at both positive and negative frequencies with respect to water resonance and an image with no saturation; and
(vi) displaying the lactate-mediated CEST contrast image as an indication of the level of expression of lactate.